Sam Brusco, Associate Editor01.25.22
Johnson & Johnson today released its fourth-quarter and full year fiscal 2021 financial performance results. Overall, reported sales for the global conglomerate rose 13.6 percent to about $93.8 billion. Net earnings also rose healthily—41.9 percent to about $20.9 billion.
The boost was mainly powered by international sales, which rose 18.2 percent to about $46.6 billion U.S. sales were still strong, however, with a 9.3 percent increase to about $47.2 billion in sales.
The company’s Medical Devices segment achieved the largest percentage increase for the year. The business accrued about $27.1 billion in proceeds last year, representing an impressive 17.9 percent (16.8 percent adjusted operational) improvement over the year prior. The company cited the market recovery from COVID-19 impacts and associated medical procedure deferral the prior year that struck the franchise’s Surgery, Interventional Solutions, Vision, and Orthopaedics businesses.
Notably released in J&J’s Medical Devices business in the final quarter of last year was the U.S. Food and Drug Administration (FDA) approval of MENTOR subsidiary’s MemoryGel BOOST breast implant.
Last quarter, the company also began a partnership with Microsoft to further enable its digital surgery ecosystem, leveraging the Microsoft Cloud to help improve outcomes and strengthen device connectivity, insights, and intelligence.
J&J’s Acclarent business released its TruSeg and TruPath AI-powered software for the TruDi navigation system for ear, nose, and throat (ENT) surgeries last week.
J&J’s COVID-19 vaccine booster shot was also granted emergency use authorization (EUA) last quarter. In November, the company announced a planned separation of its Consumer Health business to create a new publicly traded company.
“Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and healthcare providers,” newly minted CEO Joaquin Duato told the press. “Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond.”
The boost was mainly powered by international sales, which rose 18.2 percent to about $46.6 billion U.S. sales were still strong, however, with a 9.3 percent increase to about $47.2 billion in sales.
The company’s Medical Devices segment achieved the largest percentage increase for the year. The business accrued about $27.1 billion in proceeds last year, representing an impressive 17.9 percent (16.8 percent adjusted operational) improvement over the year prior. The company cited the market recovery from COVID-19 impacts and associated medical procedure deferral the prior year that struck the franchise’s Surgery, Interventional Solutions, Vision, and Orthopaedics businesses.
Notably released in J&J’s Medical Devices business in the final quarter of last year was the U.S. Food and Drug Administration (FDA) approval of MENTOR subsidiary’s MemoryGel BOOST breast implant.
Last quarter, the company also began a partnership with Microsoft to further enable its digital surgery ecosystem, leveraging the Microsoft Cloud to help improve outcomes and strengthen device connectivity, insights, and intelligence.
J&J’s Acclarent business released its TruSeg and TruPath AI-powered software for the TruDi navigation system for ear, nose, and throat (ENT) surgeries last week.
J&J’s COVID-19 vaccine booster shot was also granted emergency use authorization (EUA) last quarter. In November, the company announced a planned separation of its Consumer Health business to create a new publicly traded company.
“Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and healthcare providers,” newly minted CEO Joaquin Duato told the press. “Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond.”